Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

ABSTRACT: This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.

DISEASE(S): Adenocarcinoma,Colorectal Cancer,Metastases

PROVIDER: 2012161 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.

Project description: Not available

| S-EPMC4446100 | biostudies-literature

Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.

Project description: Not available

| S-EPMC4444288 | biostudies-literature

Project description:Altered microRNAs in methamphetamine-escalating dose-multiple binge mice

| PRJNA1347767 | ENA

177Lu-labeled DOTA-EB-RGD as a Candidate for Thyroid Cancer Therapy

Project description:Integrin αVβ3, a transmembrane receptor involved in tumor growth and metastasis, specifically recognizes and binds proteins with the arginylglycylaspartyl (RGD) peptide sequence. Using mRNA and/or protein expression data from 496 thyroid cancer (TC) samples in The Cancer Genome Atlas (TCGA), 14 TC cell lines, and 70 TC and 10 normal thyroid tissues, we found that papillary TC exhibits the highest αVβ3 integrin expression. We then evaluated the therapeutic efficacy of a novel radiolabeled RGD analog, 177Lu-DOTA-EB-cRGDfK, in TC. Genetic knockout and overexpression of αVβ3 in TC cell lines confirmed the target specificity of 177Lu-DOTA-EB-cRGDfK. In mouse xenograft models established from human TC cell lines with high αVβ3 expression, 177Lu-DOTA-EB-cRGDfK demonstrated superior antitumor efficacy compared with standard-of-care lenvatinib and placebo. However, no synergistic benefit was observed with combination therapy. Biodistribution studies identified the kidneys as the dose-limiting organ. RNA-seq analysis of resected tumors demonstrated that 177Lu-DOTA-EB-cRGDfK induced type I interferon response, characterized by upregulation of IFI6, IFIT1-2, MX1, compared with both lenvatinib-treated tumors and placebo. These findings identify αVβ3 integrin as a promising therapeutic target in a subset of TCs and demonstrate that 177Lu-DOTA-EB-cRGDfK exhibits superior efficacy to lenvatinib, supporting its potential clinical translation for progressive TC refractory to standard therapies.

2026-08-17 | GSE343650 | GEO

Project description:RNA sequencing of MC38 mouse tumor tissue with escalating drug dose

| PRJNA477829 | ENA

Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.

Project description: Not available

| S-EPMC3629966 | biostudies-literature

Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.

Project description: Not available

| S-EPMC4404254 | biostudies-literature

KRAS-G12D drives immunosuppression in lung adenocarcinoma through paracrine signaling

Project description:Here, we sought to understand the KRAS-G12D-dependent changes occuring in the tumor and the tumor microenvironment within the lung.

2025-01-15 | GSE281744 | GEO

Project description:Escalating dose-multiple binge methamphetamine treatment elicits cardiotoxicity involving in gut microbiota

| PRJNA918526 | ENA

Mus musculus

Project description:Escalating-dose peptide immunotherapy induces progressive immunoregulatory changes in self-reactive T cells

| PRJNA196942 | ENA